Story

Schott Pharma Lifts Full-Year Guidance on Syringe Demand Rebound

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Schott Pharma Lifts Full-Year Guidance on Syringe Demand Rebound
Text size
Background

Schott Pharma has raised its financial outlook for the 2026 fiscal year, pointing to a recovery in demand for polymer syringes and continued strong sales of glass syringes for popular GLP-1 weight-loss and diabetes drugs. The company confirmed the upgraded forecast on Wednesday alongside its third-quarter results.

Upgraded Outlook

Schott Pharma now expects full-year revenue growth of 5% to 6% on a constant exchange rate basis, an increase from its previous forecast of 2% to 5%. The company also lifted its adjusted EBITDA margin guidance to a range of 27% to 28%, up from approximately 27% previously.

The improved forecast is underpinned by a rebound in its polymer syringe business and robust, ongoing demand for high-value glass syringes, which are critical components for injectable GLP-1 therapies. The company also noted it had reached an agreement with an undisclosed major glass syringe customer that includes revenue-generating elements and compensation payments.

Third-Quarter Performance

For the third quarter, Schott Pharma reported revenue of €282 million, a 10% increase year-over-year, or 8.3% at constant exchange rates. However, profitability was pressured during the period.

Sample IUX Markets – In-articleAd
  • EBITDA: €76 million
  • EBITDA Margin: 26.8%, a decline from 32.3% in the same quarter last year.

This margin contraction was primarily attributed to lower capacity utilization for polymer syringes and costs associated with production optimization within its Drug Delivery Systems segment.

Segment Highlights

The company's performance varied across its two main divisions. The Drug Containment Solutions segment, which includes glass vials and syringes, saw revenue grow 11.3% year-over-year to €159 million, with an EBITDA margin of 23.8%.

In contrast, the Drug Delivery Systems segment posted revenue of €123 million, an 8.6% increase. However, its EBITDA margin fell significantly to 29.4% from 36.9% in the prior-year quarter, reflecting the aforementioned production challenges.

Read next

More on Stocks
Back to latest news

LATEST